Condition

Non-small Cell Lung Cancer NSCLC

ClinicalTrials.gov condition label

Clinical trials2

Recruiting0

Common interventions8

Lead sponsors shown2

Clinical trials

2 shown

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)NCT03775486 · 2018-12-21

ACTIVE_NOT_RECRUITING

Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung CancerNCT03505515 · 2017-12-07

COMPLETED

Common interventions

DurvalumabDRUG1Gemcitabine+carboplatinDRUG1Gemcitabine+cisplatinDRUG1Nab-paclitaxel+carboplatinDRUG1OlaparibDRUG1Pemetrexed+carboplatinDRUG1Pemetrexed+cisplatinDRUG1Placebo for OlaparibDRUG1

Leading sponsors

AstraZeneca1Bristol-Myers Squibb1

Trial status mix

ACTIVE_NOT_RECRUITING1

COMPLETED1

Phase mix

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.